SpringWorks appoints Martin Mackay to Board of Directors effective July 29, 2024

SpringWorks Therapeutics, Inc.

Mr. Mackay is independent under Nasdaq standards and serves as a Class II director until 2027 annual meeting.
Initial grants: options for 29,445 shares at $36.80 exercise price; RSUs for 9,963 shares.
Mackay brings 30+ years pharma/biotech R&D experience from Pfizer, AstraZeneca, and Alexion.
Compensation follows company's non-employee director policy; standard indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Martin Mackay

Director

SpringWorks Therapeutics, Inc.

Effective: 2024-07-29
Filed: July 30, 2024, 7:59 PM ET

On July 26, 2024, the Board of Directors (the “Board”) of SpringWorks Therapeutics, Inc. (the “Company”), appointed Martin Mackay as a member of the Board, effective July 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Martin Mackay was appointed as Director at SpringWorks Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 26, 2024, the Board of Directors (the “Board”) of SpringWorks Therapeutics, Inc. (the “Company”), appointed Martin Mackay as a member of the Board, effective July 29, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-083955

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.